264 related articles for article (PubMed ID: 30710016)
41. Anti-inflammatory potential of 2-styrylchromones regarding their interference with arachidonic acid metabolic pathways.
Gomes A; Fernandes E; Silva AM; Pinto DC; Santos CM; Cavaleiro JA; Lima JL
Biochem Pharmacol; 2009 Jul; 78(2):171-7. PubMed ID: 19464432
[TBL] [Abstract][Full Text] [Related]
42. An evidence-based evaluation of the gastrointestinal safety of coxibs.
Bombardier C
Am J Cardiol; 2002 Mar; 89(6A):3D-9D. PubMed ID: 11909555
[TBL] [Abstract][Full Text] [Related]
43. Effects of non-steroidal anti-inflammatory drugs on prostaglandin E2 production by cyclooxygenase-2 from endogenous and exogenous arachidonic acid in rat peritoneal macrophages stimulated with lipopolysaccharide.
Nakatsugi S; Sugimoto N; Furukawa M
Prostaglandins Leukot Essent Fatty Acids; 1996 Dec; 55(6):451-7. PubMed ID: 9014225
[TBL] [Abstract][Full Text] [Related]
44. [New NSAIDS: COX-1, COX-2, what about them?].
Peretz A
Rev Med Brux; 1998 Sep; 19(4):A399-402. PubMed ID: 9805982
[TBL] [Abstract][Full Text] [Related]
45. Targeting inhibition of COX-2: a review of patents, 2002-2006.
da Cunha EF; Ramalho TC; Josa D; Caetano MS; de Souza TC
Recent Pat Inflamm Allergy Drug Discov; 2007 Jun; 1(2):108-23. PubMed ID: 19075973
[TBL] [Abstract][Full Text] [Related]
46. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene.
Baek SJ; Wilson LC; Lee CH; Eling TE
J Pharmacol Exp Ther; 2002 Jun; 301(3):1126-31. PubMed ID: 12023546
[TBL] [Abstract][Full Text] [Related]
47. Cyclooxygenase-2 biology.
Clària J
Curr Pharm Des; 2003; 9(27):2177-90. PubMed ID: 14529398
[TBL] [Abstract][Full Text] [Related]
48. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
49. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
Blain H; Jouzeau JY; Netter P; Jeandel C
Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595
[TBL] [Abstract][Full Text] [Related]
50. Adverse effects of COX-2 inhibitors.
Sharma JN; Jawad NM
ScientificWorldJournal; 2005 Aug; 5():629-45. PubMed ID: 16113940
[TBL] [Abstract][Full Text] [Related]
51. COX inhibitors: a patent review (2011 - 2014).
Consalvi S; Biava M; Poce G
Expert Opin Ther Pat; 2015; 25(12):1357-71. PubMed ID: 26566186
[TBL] [Abstract][Full Text] [Related]
52. [Cyclooxygenases, lipoxygenases, their targeted drugs and the prevention of Alzheimer's disease].
Shen JN; Xu LX; Wang R
Yao Xue Xue Bao; 2013 Dec; 48(12):1743-54. PubMed ID: 24689230
[TBL] [Abstract][Full Text] [Related]
53. Synthesis, biological evaluation, docking study and ulcerogenicity profiling of some novel quinoline-2-carboxamides as dual COXs/LOX inhibitors endowed with anti-inflammatory activity.
Abdelrahman MH; Youssif BGM; Abdelgawad MA; Abdelazeem AH; Ibrahim HM; Moustafa AEGA; Treamblu L; Bukhari SNA
Eur J Med Chem; 2017 Feb; 127():972-985. PubMed ID: 27837994
[TBL] [Abstract][Full Text] [Related]
54. PGE synthase inhibitors as an alternative to COX-2 inhibitors.
Jachak SM
Curr Opin Investig Drugs; 2007 May; 8(5):411-5. PubMed ID: 17520870
[TBL] [Abstract][Full Text] [Related]
55. Cyclooxygenase-2 inhibitors: a new approach to the therapy of ocular inflammation.
Masferrer JL; Kulkarni PS
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S35-40. PubMed ID: 9154274
[TBL] [Abstract][Full Text] [Related]
56. Nonsteroidal anti-inflammatory drug-activated gene-1 plays a role in the impairing effects of cyclooxygenase inhibitors on gastric ulcer healing.
Colucci R; Antonioli L; Bernardini N; Ippolito C; Segnani C; Awwad O; Tuccori M; Blandizzi C; Scarpignato C; Fornai M
J Pharmacol Exp Ther; 2012 Jul; 342(1):140-9. PubMed ID: 22495067
[TBL] [Abstract][Full Text] [Related]
57. Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases.
Ferrer MD; Busquets-Cortés C; Capó X; Tejada S; Tur JA; Pons A; Sureda A
Curr Med Chem; 2019; 26(18):3225-3241. PubMed ID: 29756563
[TBL] [Abstract][Full Text] [Related]
58. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.
Attiga FA; Fernandez PM; Weeraratna AT; Manyak MJ; Patierno SR
Cancer Res; 2000 Aug; 60(16):4629-37. PubMed ID: 10969817
[TBL] [Abstract][Full Text] [Related]
59. Synthesis, anti-inflammatory activity and molecular docking studies of 2,5-diarylfuran amino acid derivatives.
Stefani HA; Botteselle GV; Zukerman-Schpector J; Caracelli I; da Silva Corrêa D; Farsky SH; Machado ID; Santin JR; Hebeda CB
Eur J Med Chem; 2012 Jan; 47(1):52-8. PubMed ID: 22071254
[TBL] [Abstract][Full Text] [Related]
60. Structural basis of fatty acid substrate binding to cyclooxygenase-2.
Vecchio AJ; Simmons DM; Malkowski MG
J Biol Chem; 2010 Jul; 285(29):22152-63. PubMed ID: 20463020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
